2022 mAbTalk symposium

Emerging targets for immuno-oncology

May 21, 2022, 8 p.m. (US EDT) | May 22, 2022, 8 a.m. (Beijing)

Live on Zoom, Free for Everyone

Register Now

Overview

With the development of biotechnology, immunotherapy has made significant progress and has become a novel cancer treatment. In particular, antibody therapies such as anti-CTLA-4 antibodies, anti-PD-1 antibodies, and anti-PD-L1antibodies have transformed certain cancers into chronic diseases.

Despite people having great expectations for cancer immunotherapy, the development of immunotherapy has several challenges. For example, response rates to immunotherapy are quite low in tumors that have limited T-cell infiltration. Tumor cells can also escape immune system surveillance and develop drug resistance due to reduced mutational load (TMB). In addition, the tumor immunosuppressive microenvironment can make the treatment ineffective. These difficulties have caused concerns for cancer immunotherapy. However, breakthroughs have been made in the recent years.

The first breakthrough was the combination therapy. The combination of the anti-CTLA-4 antibody Ipilimumab with the anti-PD-1 antibody Nivolumab has doubled the progression-free survival rate in metastatic melanoma patients. In addition, the combination of the anti-LAG-3 antibody Relatlimab and the anti-PD-1 antibody Nivolumab has increased progression-free survival by 50%, and reduced the side effects of the anti-CTLA-4 antibody by at least 50%. In fact, this combination strategy has revolutionized the first-line therapy for metastatic melanoma.

Second, the emergence of new targets has also opened an entirely new field for cancer immunotherapy. The combination of the anti-PD-L1 antibody Tecentrip with the antibody targeting the new target TIGIT Tiragolumab has become the first-line treatment of non-small cell lung cancer. In patients with PD-L1 Tumor Proportion Score (TPS) ≥ 50%, this new therapy has increased the median progression-free survival of 4.1 months for the anti-PD-L1 antibody monotherapy to 16.6 months, and reduced the death rate by 71%. In addition, several T cell therapies, NK cell therapy, macrophage cell therapy, and T-reg cell therapies are in the clinical trials and may soon provide exciting outcomes.

In view of the recent exciting development of cancer immunotherapy, the Chinese Antibody Society (CAS) and the CAS’s journal Antibody therapeutics will together hold the Chinese Antibody Society mAbTalkTM symposium with the title "Emerging Targets for Immuno-oncology" on Saturday, May 21, 2022, at 8:00 pm (US Eastern time) / Sunday, May 22 at 8:00 am (Beijing time). We have invited several established academic experts in the field of immunotherapy to discuss various novel cancer immunotherapies. This symposium will be broadcast live through the Zoom platform.

Sponsors

Platinum

Gold

Speakers

Hover above speaker cards to read bio

bio

Mitchell Ho

Senior Investigator, NCI

bio

Dimiter Dimitrov

Professor, University of Pittsburgh

bio

Rongze Lu

Assistant Professor, UT Austin UCSF

bio

Jun Wang

Assistant Professor, NYU

bio

Rui Su

Assistant Professor, City of Hope

bio

Longxing Cao

Assistant Professor, Westlake University

Agenda

Starts at 05/21/2022 8 p.m. (US EDT) | 05/22/2022 8 a.m. (Beijing)

Hover to view abstract

05/21/2022 8:10 p.m. EDT

Session 1 Glypicans as CART Targets in Solid Tumors

Mitchell Ho, Senior Investigator, NCI

05/21/2022 8:40 p.m. EDT

Session 1 FGL1 LAG3 as emergent target for immunotherapy of cancer and beyond

Jun Wang, Assistant Professor, NYU

05/21/2022 9:10 p.m. EDT

Session 1 RNA methylation in leukemogenesis and leukemia immunity

Rui Su, Assistant Professor, City of Hope

05/21/2022 9:40 p.m. EDT

Break acknowledgement to volunteers sponsor video

Organizer, TBD, The Chinese Antibody Society

05/21/2022 10:10 p.m. EDT

Session 2 Human VH domains against viruses and cancer

Dimiter Dimitrov, Professor, University of Pittsburgh

05/21/2022 10:40 p.m. EDT

Session 2 PP2A a novel immunotherapy target

Rongze Lu, Assistant Professor, UT Austin UCSF

05/21/2022 11:10 p.m. EDT

Session 2 Robust de novo design of protein binding proteins from target structural information alone

Longxing Cao, Assistant Professor, Westlake University

05/21/2022 11:40 p.m. EDT

Close Remarks

Organizer, TBD, The Chinese Antibody Society

FAQ of Meeting Registration

If you have any questions, feel free to reach out to us
This web app is a Python Django project independently coded (frontend+backend+deployment on AWS) by Xin Yu (Github, LinkedIn) in her volunteer capacity at the Chinese Antibody Society. Contents are maintained by CAS IT team. If you're interested in participating in the future development of this web app, please submit a volunteer application and request an interview with the IT team. We require a minimum of 2 years experience as a Django developer. © Chinese Antibody Society 2021. All Rights Reserved. Legal Disclaimer
Icon